Neurocutaneous melanosis is characterized by the presence of congenital melanocytic nevi on the skin and melanocytic tumors in the leptomeninges of the central nervous system
WeightCare accommodates these transitions through their physician consultations, using a dose conversion chart to calculate equivalent starting doses on the new medication
On your syringe, this means drawing to the 10-unit mark
Potential risks include: Enhanced gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) Increased risk of nutritional deficiencies and protein malnutrition Potential worsening of gastroesophageal reflux symptoms Dehydration risk and acute kidney injury, particularly during dose escalation Increased risk of gallbladder disease and complications Risk of intestinal obstruction or ileus Diabetic retinopathy progression in patients with diabetes, particularly with rapid glycemic improvement Hypoglycemia risk, particularly in patients on insulin or sulfonylureas Cost considerations and insurance coverage challenges Rare but serious risks including pancreatitis and thyroid C-cell tumors (boxed warning) Clinicians must engage in shared decision-making with patients, carefully weighing these potential benefits against risks in the context of individual patient circumstances, surgical outcomes, comorbidities, and treatment goals
